The Antiparkinsonian Activity of CQA 206–291, a New D2Dopamine Receptor Agonist
作者:
J. Temlett,
N. Quinn,
C. Marsden,
X. Lataste,
A. Jaton,
期刊:
Clinical Neuropharmacology
(OVID Available online 1989)
卷期:
Volume 12,
issue 1
页码: 55-59
ISSN:0362-5664
年代: 1989
出版商: OVID
关键词: CQA 206–291;Parkinson's disease
数据来源: OVID
摘要:
SummaryCQA 206–291, a new D2dopamine receptor agonist with a biphasic dopaminergic profile, was given to six patients with idiopathic Parkinson's disease after overnight drug withdrawal. With incremental single oral doses of CQA, a dose-related, clinically significant, and prolonged antiparkinsonian effect was observed. Most subjects experienced drowsiness after the drug while a minority of subjects experienced nausea and/or vomiting or postural hypotension. Further study of this drug in humans is indicated.
点击下载:
PDF
(222KB)
返 回